Q3 FY26 · Ended Sep 25, 2026 · View SEC filing
Most of this quarter's growth was bought
Core sales grew 3.0%, so acquired businesses did more than twice the work of the ones Danaher already owned.
For investorsWhat Diagnostics margins depend on after Masimo
For foundersSelling the instrument to own the consumables
Biotechnology earned a 26.4% margin to Life Sciences' 13.9%, so drug-making supplies carry far more profit per dollar.
Core sales grew 3.0%, but nearly twice that without respiratory tests, whose demand follows the flu season.
Operating profit rose 7.9%, yet net earnings rose 36.0% because taxes swung from a charge to a benefit.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Danaher Corporation from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
